Pérez-Cózar Francisco, Cal-Sabater Paloma, Rybakowska Paulina, Arribas-Rodríguez Elisa, Fiz-López Aida, García-Blesa Antonio, Hernández Juan, Gutiérrez Sara, Tellería Pablo, Novoa Cristina, Rello Silvia Rojo, De Prado Ángel, Pérez Cándido, Sedano Rosa, Domínguez-Gil Marta, Peñarrubia María Jesús, Pieren Daan K J, Garrote José A, Arranz Eduardo, Eiros José María, Tamayo Eduardo, Orduña Antonio, van Els Cécile A C M, Dueñas Carlos, Marañón Concepción, Bernardo David, Cuesta-Sancho Sara
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Mucosal Immunology Lab. Institute of Biomedicine and Molecular Genetics (IBGM, University of Valladolid-CSIC), Valladolid, Spain.
J Med Virol. 2025 Jun;97(6):e70435. doi: 10.1002/jmv.70435.
Long-term consequences of SARS-CoV-2 infection are unknown since recovered individuals can experience symptoms and latent viral reactivation for months. Indeed, acute post-infection sequelae have also been observed in other respiratory viral infections, including influenza. To characterize post-COVID-19 and post-influenza induced alterations to the cellular immunome, peripheral blood mononuclear cells (PBMCs) were obtained from patients 3 months after recovery from COVID-19 (n = 93) or influenza (n = 25), and from pre-pandemic healthy controls (n = 25). PBMCs were characterized using a 40-plex mass cytometry panel. Principal component analysis (PCA), classification models, and K-means clustering were subsequently applied. PCA identified distinct immune profiles between cohorts, with both post-COVID and post-flu patients displaying an altered chemokine receptor expression compared to pre-pandemic healthy controls. These alterations were more prominent in post-COVID patients since they exhibited highly increased expression of chemokine receptors CXCR3 and CCR6 by various lymphoid populations, while post-influenza patients mainly showed a decrease in CCR4 expression by naïve T cells, monocytes, and conventional dendritic cells. Classification models using immunophenotyping data confirm the three groups, while K-means clustering revealed two subgroups among post-COVID patients, with younger patients showing more pronounced immune alterations in the chemokine receptor profile, independently of long COVID symptoms. In conclusion, post-COVID and post-influenza patients exhibit distinct and unique persistent immune alterations. Understanding these altered immune profiles can guide targeted therapies for post-COVID syndrome and highlight differences in immune recovery from various respiratory infections.
由于康复个体可能在数月内出现症状和潜伏病毒再激活,因此新冠病毒感染的长期后果尚不清楚。事实上,在包括流感在内的其他呼吸道病毒感染中也观察到了急性感染后后遗症。为了表征新冠和流感感染后诱导的细胞免疫组改变,从新冠康复3个月后的患者(n = 93)或流感康复3个月后的患者(n = 25)以及疫情前的健康对照(n = 25)中获取外周血单核细胞(PBMC)。使用40参数质谱流式细胞术面板对PBMC进行表征。随后应用主成分分析(PCA)、分类模型和K均值聚类。PCA确定了不同队列之间不同的免疫特征,与疫情前的健康对照相比,新冠康复患者和流感康复患者均表现出趋化因子受体表达改变。这些改变在新冠康复患者中更为突出,因为他们的各种淋巴细胞群体趋化因子受体CXCR3和CCR6表达大幅增加,而流感康复患者主要表现为幼稚T细胞、单核细胞和传统树突状细胞的CCR4表达降低。使用免疫表型数据的分类模型证实了这三组,而K均值聚类在新冠康复患者中揭示了两个亚组,年轻患者在趋化因子受体谱中表现出更明显的免疫改变,与长期新冠症状无关。总之,新冠康复患者和流感康复患者表现出独特且持久的免疫改变。了解这些改变的免疫特征可以指导针对新冠后综合征的靶向治疗,并突出各种呼吸道感染免疫恢复的差异。